Skip to Content

MYLAN 2250 MYLAN 2250 (Mycophenolate Mofetil 250 mg)

Pill with imprint MYLAN 2250 MYLAN 2250 is Tan / Purple, Capsule-shape and has been identified as Mycophenolate mofetil 250 mg. It is supplied by Mylan Pharmaceuticals Inc..

Mycophenolate mofetil is used in the treatment of nephrotic syndrome; organ transplant, rejection prophylaxis; autoimmune hepatitis; bullous pemphigoid; graft-versus-host disease (and more), and belongs to the drug class selective immunosuppressants. There is positive evidence of human fetal risk during pregnancy. Mycophenolate mofetil 250 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for MYLAN 2250 MYLAN 2250

Mycophenolate mofetil 250 mg MYLAN 2250 MYLAN 2250
Mycophenolate mofetil 250 mg MYLAN 2250 MYLAN 2250
Mycophenolate mofetil 250 mg MYLAN 2250 MYLAN 2250

Mycophenolate mofetil

MYLAN 2250 MYLAN 2250
250 mg
Tan / Purple
19.00 mm
Prescription only
Drug Class:
Selective immunosuppressants
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Mylan Pharmaceuticals Inc.
Inactive Ingredients:
silicon dioxide
croscarmellose sodium
magnesium stearate
microcrystalline cellulose
corn starch
sodium lauryl sulfate
ferrosoferric oxide
FD&C Blue No. 2
ferric oxide red
titanium dioxide
ferric oxide yellow
propylene glycol
Note: Inactive ingredients may vary.

Other Labelers / Repackagers:

NDC CodeLabeler / Repackager
51079-0721 UDL Laboratories Inc.

Get help with Imprint Code FAQs.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2018, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.